Home > Journals > Chirurgia > Past Issues > Chirurgia 2018 October;31(5) > Chirurgia 2018 October;31(5):168-78

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Chirurgia 2018 October;31(5):168-78

DOI: 10.23736/S0394-9508.18.04767-8

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: Italian

Morbidity and mortality after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy in thirty peritoneal carcinomatosis patients: experience of a single center

Giada DI FLUMERI , Fabio PACELLI, Carlo ABATINI, Claudio LODOLI, Andrea DI GIORGIO

Catholic University of the Sacred Heart, Rome, Italy


PDF


BACKGROUND: Peritoneal carcinomatosis (PC) represents frequently the evolution of an abdominal cancer. Cytoreductive surgery (CRS) with intraperitoneal hyperthermic chemotherapy (HIPEC) can improve oncological outcomes but is associated with high morbidity and mortality. The aim of this study is to analyze the morbidity and mortality of this procedure.
METHODS: Thirty patients with PC had CRS + HIPEC at the Catholic University of the Sacred Heart, Rome, from January 2015 to December 2016. An uni- and multivariate statistical analysis was conducted to evaluate the impact of demographic, pathological, surgery-related and HIPEC-related variables on 30-day morbidity and mortality. The Common Terminology for Adverse Event v. 4.03 was used to classify complications. SPSS version 20 for Windows was used to perform statistical analysis.
RESULTS: Overall morbidity and mortality rates were 43.3% and 3.3%, respectively. Postoperative major complications (CTACE≥3) occurred in 13.3% of patients. Among the variables associated with major complications at univariate analysis (ECOG performance status, prior chemotherapy, number of anastomosis, duration of operation and drug used for HIPEC) only the number of anastomoses resulted statistically significant at multivariate analysis.
CONCLUSIONS: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is a feasible option for patient with peritoneal carcinomatosis in our hospital. The morbidity and mortality rates are acceptable, and we have identified some variables to improve the selection of patients.


KEY WORDS: Peritoneal neoplasms - Cytoreduction surgical procedures - Induced hyperthermia - Morbidity - Mortality

top of page